---
title: "Eliquis (apixaban) in nonvalvular atrial fibrillation: Specific populations questions"
description: "Specific populations questions on Eliquis (apixaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Can Eliquis be used in patients with prosthetic or mechanical heart valves? Is Eliquis recommended for patients with antiphospholipid syndrome? Does Eliquis need a dose adjustment for kidney impairment in atrial fibrillation? Can Eliquis be used in patients with atrial fibrillation on dialysis? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/specific-populations"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Eliquis (apixaban) in nonvalvular atrial fibrillation: Specific populations questions

Manufacturer: Bristol-Myers Squibb Company; Pfizer Inc  
Prescribing information: [Eliquis](https://packageinserts.bms.com/pi/pi_eliquis.pdf)

## Specific populations

<a id="eliquis-prosthetic-valves"></a>

### Can Eliquis be used in patients with prosthetic or mechanical heart valves?

> “Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Prosthetic%20Heart%20Valves%3A%20The%20safety,not%20recommended%20in%20these%20patients.)

<a id="eliquis-antiphospholipid-syndrome"></a>

### Is Eliquis recommended for patients with antiphospholipid syndrome?

> “Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome (APS): Direct-acting oral anticoagulants (DOACs), including ELIQUIS, are not recommended for use in patients with triple-positive APS. For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti–beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Increased%20Risk%20of%20Thrombosis%20in,with%20vitamin%20K%20antagonist%20therapy.)

<a id="eliquis-renal-dosing"></a>

### Does Eliquis need a dose adjustment for kidney impairment in atrial fibrillation?

> “No dose adjustment is recommended for nonvalvular atrial fibrillation patients unless at least 
> 2 of the following patient characteristics (age greater than or equal to 80 years, body weight less 
> than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL) are present.”

Source: [ELIQUIS: Prescribing information, page 9, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=9)

> “Renal excretion
> accounts for about
> 27%
> of total clearance”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=Renal%20excretion,of%20total%20clearance)

> “ELIQUIS is eliminated in both urine and feces. Biliary and direct intestinal excretion contributes to elimination of ELIQUIS in the feces”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=ELIQUIS%20is%20eliminated%20in%20both,of%20ELIQUIS%20in%20the%20feces)

<a id="eliquis-dialysis"></a>

### Can Eliquis be used in patients with atrial fibrillation on dialysis?

> “Clinical efficacy and safety studies with ELIQUIS did not enroll patients with ESRD on dialysis
> In patients with ESRD maintained on intermittent hemodialysis, administration of ELIQUIS at the usually recommended dose will result in concentrations of apixaban and pharmacodynamic activity similar to those observed in the ARISTOTLE study
> It is not known whether these concentrations will lead to similar stroke reduction and bleeding risk in patients with ESRD on dialysis as were seen in ARISTOTLE”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=In%20patients%20with%20ESRD%20maintained%20on%20intermittent%20hemodialysis%2C%20administration%20of,as%20were%20seen%20in%20ARISTOTLE)

> “Hemodialysis in ESRD subjects:  Systemic exposure to apixaban administered as a single 5 mg 
> dose in ESRD subjects dosed immediately after the completion of a 4-hour hemodialysis session 
> (postdialysis) is 36% higher when compared to subjects with normal renal function (Figure 3). 
> The systemic exposure to apixaban administered 2 hours prior to a 4-hour hemodialysis session 
> with a dialysate flow rate of 500 mL/min and a blood flow rate in the range of 350 to 500 mL/min 
> is 17% higher compared to those with normal renal function. The dialysis clearance of apixaban 
> is approximately 18 mL/min. The systemic exposure of apixaban is 14% lower on dialysis when 
> compared to not on dialysis.”

Source: [ELIQUIS: Prescribing information, page 9, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=9)

<a id="eliquis-hepatic-impairment"></a>

### Can Eliquis be used in patients with liver disease?

> “MILD
> hepatic impairment
> (Child-Pugh class A)	No dose adjustment required.<sup>2</sup>
>
> MODERATE
> hepatic impairment
> (Child-Pugh class B)	There is limited clinical experience with ELIQUIS in patients with moderate hepatic impairment; dosing recommendation cannot be provided.<sup>2</sup>
>
> SEVERE
> hepatic impairment
> (Child-Pugh class C)	ELIQUIS is not recommended.<sup>2</sup>”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=with%20hepatic%20impairment-,MILD,ELIQUIS%20is%20not)

<a id="eliquis-elderly"></a>

### Is Eliquis effective and safe in older adults with atrial fibrillation?

> “Of the total subjects in the ARISTOTLE and AVERROES clinical studies, >69% were 65 years 
> of age and older, and >31% were 75 years of age and older.”

Source: [ELIQUIS: Prescribing information, page 7, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=7)

> “No clinically significant differences in safety or effectiveness were observed when comparing 
> subjects in different age groups.”

Source: [ELIQUIS: Prescribing information, page 7, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=7)

> “Stroke and Systemic Embolism Hazard Ratios by Baseline Characteristics”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

> “n of Events / N of Patients (% per year)
> Subgroup
> Apixaban
> Warfarin
> Hazard Ratio (95% CI)”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

> “Age
> <65 (30%)
> 51 / 2731 (1.0)
> 44 / 2740 (0.9)
> 1.16 (0.77, 1.73)
> ≥65 and <75 (39%)
> 82 / 3539 (1.3)
> 112 / 3513 (1.7)
> 0.72 (0.54, 0.96)
> ≥75 (31%)
> 79 / 2850 (1.6)
> 109 / 2828 (2.2)
> 0.71 (0.53, 0.95)”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

> “Major Bleeding Hazard Ratios by Baseline Characteristics”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

> “n of Events / N of Patients (% per year)
> Subgroup
> Apixaban
> Warfarin
> Hazard Ratio (95% CI)”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

> “Age
> <65 (30%)
> 56 / 2723 (1.2)
> 72 / 2732 (1.5)
> 0.78 (0.55, 1.11)
> ≥65 and <75 (39%)
> 120 / 3529 (2.0)
> 166 / 3501 (2.8)
> 0.71 (0.56, 0.89)
> ≥75 (31%)
> 151 / 2836 (3.3)
> 224 / 2819 (5.2)
> 0.64 (0.52, 0.79)”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

Note: Age of 80 years or older is one of the criteria for the 2.5 mg dose.

<a id="eliquis-pregnancy"></a>

### Can Eliquis be used during pregnancy?

> “The limited available data on ELIQUIS use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. Treatment may increase the risk of bleeding during pregnancy and delivery, and in the fetus and neonate.
> Labor or delivery: ELIQUIS use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. Consider use of a shorter acting anticoagulant as delivery approaches.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=The%20limited%20available%20data%20on,acting%20anticoagulant%20as%20delivery%20approaches.)

<a id="eliquis-breastfeeding"></a>

### Can patients breastfeed while taking Eliquis?

> “Breastfeeding is not recommended during treatment with ELIQUIS.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Breastfeeding%20is%20not%20recommended%20during%20treatment%20with%20ELIQUIS.)

> “There are no data on the presence of apixaban or its metabolites in human milk, the effects 
> on the breastfed child, or the effects on milk production. Apixaban and/or its metabolites were 
> present in the milk of rats (see Data) . Because human exposure through milk is unknown, 
> breastfeeding is not recommended during treatment with ELIQUIS.”

Source: [ELIQUIS: Prescribing information, page 7, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=7)

<a id="eliquis-uterine-bleeding"></a>

### Can Eliquis cause heavy uterine or menstrual bleeding?

> “Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician. The risk of clinically significant uterine bleeding, potentially requiring gynecological surgical interventions, identified with oral anticoagulants including ELIQUIS should be assessed in these patients and those with abnormal uterine bleeding.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Females%20of%20reproductive%20potential%20requiring,those%20with%20abnormal%20uterine%20bleeding.)

## Related pages
- [Medical information: Eliquis (apixaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/access-and-coverage)
